SLC6A19 inhibition was efficacious in Pahenu2 mice across a broad range of elevated basal plasma Phe levels, from classic PKU (Phe > 1,200 μM) to hyperphenylalaninemia (Phe > 360 but < 600 μM). This evidence concerns the gene SLC6A19 and phenylketonuria.